|
Feds Threaten to Pull ProAmatine for Lack of Postmarket Data - PharmExec.com (blog) |
|
|
|
PharmExec.com (blog)... patients,” stated Norman Stockbridge, director of the Division of Cardiovascular and Renal Drugs in the FDA's Center for Drug Evaluation and Research. ...
|